Prevalence and Prognostication of CD5+ Mature T-Cell Lymphomas.

Autor: Elghawy O; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Cao M; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Thomas Jefferson University Department of Pharmacology, Physiology and Cancer Biology, Philadelphia, PA 19107, USA., Xu J; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Thomas CJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Carter JS; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Tavakkoli M; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Ruella M; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2024 Oct 09; Vol. 16 (19). Date of Electronic Publication: 2024 Oct 09.
DOI: 10.3390/cancers16193430
Abstrakt: Background: T-cell lymphomas (TCLs) are a group of heterogenous cancers with poor rates and duration of response. There remains a great challenge in risk stratification of these cancers. Cluster of differentiation (CD) 5 has shown prognostic implication in many subtypes of B-cell lymphoma; however, its role in TCLs is not known. Methods: We performed a single-institution retrospective analysis of newly diagnosed patients with TCL. CD5 positivity was determined based on positive results via immunohistochemistry and/or flow cytometry. We used univariate and multivariable analysis of biological factors to assess their association with survival outcomes. Results: A total of 194 patients with TCL spanning 14 subtypes were identified. CD5 positivity was noted in 63% of patients, with the highest proportion of CD5 expression in TFH TCL (93.9%), PTCL-NOS (82.9%), and ATLL (77.8%) ( p = 0.00004). Older age at diagnosis ( p = 0.001), stage III or IV disease ( p = 0.05), and bone marrow involvement ( p = 0.003) were also associated with CD5 expression. Complete response rates were numerically lower in patients with CD5+ TCL across all subtypes. OS/PFS was not statistically associated with CD5 status in the overall cohort; however there was significantly decreased OS in CD5+ TFH TCL ( p = 0.04) and CD5+ ATLL ( p = 0.04) patients. Conclusions: This study represents the first to examine CD5 expression as a prognostic biomarker for outcomes in TCL. The frequent expression of CD5 in the most common nodal TCL in the Western world underpins its potential as an attractive target for cellular therapies. Confirmation of these findings in a larger cohort and investigation of potential pathophysiological mechanisms explaining our observations are planned.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje